Non-Invasive Multimarker Strategy Combining IL-17A, Neutrophil–Albumin Ratio, and Fecal Calprotectin for Accurate Discrimination of IBD from IBS-D
Gamal Othman, Maysaa El Sayed Zaki, Nader Elmalki Elmalki, Abdelnaser A. Badawy, Samir A. Afifi · 2026
Read Non-Invasive Multimarker Strategy Combining IL-17A, Neutrophil–Albumin Ratio, and Fecal Calprotectin for Accurate Discrimination of IBD from IBS-D by Gamal Othman, Maysaa El Sayed Zaki, Nader Elmalki Elmalki, Abdelnaser A. Badawy, Samir A. Afifi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13300525.txt.
Description
Gamal Othman and co-authors test a three-marker blood and stool panel for telling inflammatory bowel disease from diarrhea-predominant irritable bowel syndrome, in a 2026 case-control study of Egyptian patients. The conditions overlap in symptoms, and single markers lack precision. The study enrolled one hundred patients in each of the two disease groups plus one hundred healthy controls, measuring interleukin-17A, a neutrophil-to-albumin ratio, and fecal calprotectin.
All three markers rose in steps from controls through irritable bowel patients to inflammatory disease, with the highest values in the last group. Infection status inside the irritable bowel group made no difference. The ratio marker alone performed best among singles, while the combined model reached clearly better discrimination, near ninety percent sensitivity and ninety-six percent specificity. Because the model was built and tested in one cohort, the authors insist on outside validation before clinical use.
Catalog record
| CREATOR | Gamal Othman, Maysaa El Sayed Zaki, Nader Elmalki Elmalki, Abdelnaser A. Badawy, Samir A. Afifi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |